MDR 0.00% 45.0¢ medadvisor limited

Ann: Q3 FY24 MDR Quarterly Update, page-3

  1. 2,849 Posts.
    lightbulb Created with Sketch. 1058

    3Q24 has a gross profit of $15.3m

    Their operating costs (based on 1H24) was ~$34m (excl Depr & Amort) or ~$33m excluding finance costs (not sure why they are not paying down that loan), so if they can hit a similar gross profit for for 4Q24, 2H24 will be incredibly close to being EBITDA positive on its own.

    Given 4Q24 US projected revenues already contracted for, and Aus revenues are recurring (plus additional transaction fees etc), it seems that Ratliff has delivered as he promised.....positive EBITDA for FY24.

    1H24 EBITDA +10m
    2H24 Gross profit of ~30m, costs of ~34m +> EBITDA of -4m
    Which means an EBITDA of ~6m for FY2024

    Question now is how much more can they deliver.....seems like THRIV is gaining traction and the added bonus seems to be that it improves margins in the US........if they can continue to grow that, then the bottom line improves and chance for rerate

 
watchlist Created with Sketch. Add MDR (ASX) to my watchlist
(20min delay)
Last
45.0¢
Change
0.000(0.00%)
Mkt cap ! $247.6M
Open High Low Value Volume
45.0¢ 45.0¢ 45.0¢ $18.61K 41.36K

Buyers (Bids)

No. Vol. Price($)
1 198 44.5¢
 

Sellers (Offers)

Price($) Vol. No.
45.0¢ 221082 5
View Market Depth
Last trade - 12.26pm 30/05/2024 (20 minute delay) ?
Last
44.0¢
  Change
0.000 ( 1.12 %)
Open High Low Volume
44.0¢ 44.0¢ 44.0¢ 2202
Last updated 14.15pm 30/05/2024 ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.